aod9604 human clinical trials weight loss results AOD 9604 vs. Semaglutide: A Comparison Obesity Pharmacotherapy: Current Perspectives and

However, in the pivotal Phase IIb trial, it failed to demonstrate statistically significant weight loss compared to placebo at the primary endpoint, leading the developer (Metabolic Pharmaceuticals Ltd.) to terminate the commercial program

For current information on peptide availability and regulatory changes, see our FDA peptide crackdown 2026 analysis

Discard after 28 days

Rather than asking what is the dose, which presumes the compound is already the answer, the stronger questions open up the actual decision

This approach maintains more consistent peptide levels throughout the day and may provide advantages for individuals using doses at the higher end of the range (450-500mcg daily)